Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures
News May 03, 2013
Zytoprotec has announced that it has raised EUR 2 million in financing from new investor Baxter Ventures towards a EUR 4 million Series A financing.
Baxter Ventures is an investment initiative established by Baxter International in 2011 to invest up to USD 200 million in promising companies.
As a result of the financing Norbert Riedel, Ph.D., Baxter’s Chief Science and Innovation Officer will join Zytoprotec’s Supervisory Board.
Zytoprotec’s most advanced product, PD-protec™, is a next-generation solution for peritoneal dialysis (PD) designed to actively protect abdominal cells.
The peptide used as the cytoprotective component of PD-protec™ is patent-protected by Zytoprotec. The product has completed a Phase I/II trial in 2012 and a Phase II trial is planned to commence in early 2013.
“We are very pleased to add Baxter to our investor base, given the company’s longstanding expertise and leadership in PD therapy”, Peter C. Weilguni, Chief Executive Officer of Zytoprotec, commented.
Weilguni continued, “We welcome Dr. Riedel to the Board of our Company as we are preparing PD-protec™ for a Phase II clinical trial.”
“Zytoprotec offers an exciting technology opportunity to protect the peritoneal membrane”, commented Norbert Riedel, Ph.D, Baxter’s Chief Science and Innovation Officer.
Riedel continued, “A peritoneal dialysis solution that holds the potential to prolong treatment time on PD would bring significant benefits to patients with kidney disease.”
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE